These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29740404)

  • 1. Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model.
    Gur D; Glinert I; Aftalion M; Vagima Y; Levy Y; Rotem S; Zauberman A; Tidhar A; Tal A; Maoz S; Ber R; Pass A; Mamroud E
    Front Microbiol; 2018; 9():741. PubMed ID: 29740404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
    Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
    Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Neutrophil Primary Granule Release during Yersinia pestis Pulmonary Infection.
    Eichelberger KR; Jones GS; Goldman WE
    mBio; 2019 Dec; 10(6):. PubMed ID: 31822588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model.
    Olson RM; Anderson DM
    PLoS One; 2019; 14(5):e0217440. PubMed ID: 31121001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92.
    Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Baze WB; Suarez G; Peterson JW; Chopra AK
    Microbes Infect; 2009 Feb; 11(2):205-14. PubMed ID: 19073275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized Method for Aerosol Challenge of Rodents with Yersinia pestis for Modeling Primary Pneumonic Plague.
    Anderson PE; Olson RM; Willix JL; Anderson DM
    Methods Mol Biol; 2019; 2010():29-39. PubMed ID: 31177429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague.
    Jakielaszek C; Hossain M; Qian L; Fishman C; Widdowson K; Hilliard JJ; Mannino F; Raychaudhuri A; Carniel E; Demons S; Heine HS; Hershfield J; Russo R; Mega WM; Revelli D; O'Dwyer K
    Sci Transl Med; 2022 Jun; 14(647):eabg1787. PubMed ID: 35648812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Inoculation of Mice with Yersinia pestis and Processing of Pulmonary Tissue for Analysis.
    Pechous RD
    Methods Mol Biol; 2019; 2010():17-28. PubMed ID: 31177428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo transcriptional profiling of Yersinia pestis reveals a novel bacterial mediator of pulmonary inflammation.
    Pechous RD; Broberg CA; Stasulli NM; Miller VL; Goldman WE
    mBio; 2015 Feb; 6(1):e02302-14. PubMed ID: 25691593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague.
    Fitts EC; Andersson JA; Kirtley ML; Sha J; Erova TE; Chauhan S; Motin VL; Chopra AK
    mSphere; 2016; 1(6):. PubMed ID: 27981238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yersinia pestis and pneumonic plague: Insight into how a lethal pathogen interfaces with innate immune populations in the lung to cause severe disease.
    Venugopal G; Pechous RD
    Cell Immunol; 2024 Jul; 403-404():104856. PubMed ID: 39002222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circumventing Y. pestis Virulence by Early Recruitment of Neutrophils to the Lungs during Pneumonic Plague.
    Vagima Y; Zauberman A; Levy Y; Gur D; Tidhar A; Aftalion M; Shafferman A; Mamroud E
    PLoS Pathog; 2015 May; 11(5):e1004893. PubMed ID: 25974210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spray-Dried Inhalable Powder Formulations of Gentamicin Designed for Pneumonic Plague Therapy in a Mouse Model.
    Zhu M; Zhang D; Zhang L; Zhao L; Xu L; Wang B; Zhang X; Chen J; Bei Z; Wang H; Zhou D; Yang W; Song Y
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
    Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
    J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.
    Crane SD; Banerjee SK; Pechous RD
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0127521. PubMed ID: 34780267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
    Hewitt JA; Lanning LL; Campbell JL
    Clin Infect Dis; 2020 May; 70(70 Suppl 1):S51-S59. PubMed ID: 32435803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection.
    Ponnusamy D; Fitts EC; Sha J; Erova TE; Kozlova EV; Kirtley ML; Tiner BL; Andersson JA; Chopra AK
    Infect Immun; 2015 May; 83(5):2065-81. PubMed ID: 25754198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.